NCT06608732View on ClinicalTrials.gov

Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2028

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

Inaticabtagene autoleucel

CNCT19 combined with autologous hematopoietic stem cell transplantation，Dose: （0.5 -2）x 10\^6/kg CNCT19 Cell Injection via intravenous infusion.

Trial Locations (1)

300000

RECRUITING

National Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin

Sponsors
All Listed Sponsors
collaborator

Juventas Cell Therapy Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06608732 - Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. | Biotech Hunter | Biotech Hunter